Varian Medical Systems, headquartered globally in Palo Alto, California, is the world's leading manufacturer of medical devices and software for treating cancer and other medical conditions with radiotherapy, radiosurgery, proton therapy, and brachytherapy. The company supplies informatics software for managing comprehensive cancer clinics, radiotherapy centers and medical oncology practices. Varian is a premier supplier of tubes and digital detectors for X-ray imaging in medical, scientific, and industrial applications and also supplies X-ray imaging products for cargo screening and industrial inspection.
Aspekt Solutions strives to provide the highest quality professional services with core competency in medical and industrial radiation applications - including technical expertise for consultation, development and management of applied radiation systems, including staffing and management solutions to clinics and hospitals in the business of providing radiation services. AMP has the following staff and support available for services: Clinical and Support Staff: Qualified Medical Physics (QMP) staff Qualified Medical Dosimetry staff Authorized Medical Physicist staff for licensed RAM procedures Radiation Safety Officer staff for RAM licenses Medical Health Physics staff for medical applications Medical Administrative Support staff for Accreditation Programs Qualified Experts and Licensed Inspectors (State recognized) Support and Equipment: Full Complement of Equipment for testing of: Diagnostic X-ray (Planar, Digital, CT, MRI) Nuclear Medicine (Gamma Cameras and PET systems) Health Physics needs in Nuclear Medicine Shielding Audits Full Complement of Equipment for support of: Acceptance and Commissioning of Linacs Acceptance and Commissioning of SRS systems Patient Dosimetry (OSL) Film Dosimetry (QA) LDR Prostate Seed Dosimetry
Lucata
Series B in 2021
Lucata Corporation specializes in developing advanced hardware and software technology to enhance memory utilization for various industries. Founded in 2008 and headquartered in New York, with additional offices in South Bend, Indiana, and Palo Alto, Lucata produces motherboards, node cards, and memory servers designed for high-performance analytics. The company employs patented migrating thread technology to enable organizations to perform extensive multi-hop analytics and graph analysis on massive databases, facilitating insights from complex data structures with up to one trillion vertices. Lucata's solutions cater to sectors such as financial services, cybersecurity, healthcare, and telecommunications, allowing users to leverage existing graph database software for deeper analysis without the need for extensive software layers. The company's architecture is energy-efficient, supports linear performance scaling, and significantly reduces latency, making it a powerful option for organizations tackling big data challenges.
Bendit
Series B in 2021
Bendit is a medical company focused on the development and manufacturing of innovative catheters that utilize a unique bending technology, allowing for enhanced steering capabilities in both micro diameter and traditional catheter designs. The company specializes in creating microcatheter devices that facilitate optimal navigation within the body, particularly in challenging anatomical areas. Bendit's products are designed to improve procedural efficiency by enabling healthcare professionals to reach target sites with fewer tools, thereby reducing risks and increasing the likelihood of successful outcomes. The organization is a joint venture comprising three experienced groups that bring expertise in production, quality and regulation, and medical development.
COTA Healthcare
Debt Financing in 2020
COTA, Inc. is a Boston-based company that specializes in developing a platform designed to provide data and insights related to cancer patients, aimed at guiding treatment decisions. Founded in 2011 by a team of doctors, engineers, and data scientists, COTA utilizes proprietary technology and advanced analytics to transform fragmented electronic health record (EHR) data into cohesive, research-grade information. This platform supports oncology practices and cancer centers by identifying variations in care, thus enabling the design of effective treatment programs and payment models. COTA's solutions serve a diverse range of stakeholders, including healthcare providers, payers, life sciences companies, and the FDA, ultimately striving to enhance patient outcomes and reduce healthcare costs associated with cancer care.
HistoSonics
Series C in 2020
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.
Arterys
Series C in 2020
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.
Zap Surgical Systems
Private Equity Round in 2020
Zap Surgical Systems, Inc. is a medical technology company based in San Carlos, California, founded in 2014. The company designs and manufactures the ZAP-X radiosurgery platform, which is utilized for treating brain tumors and various conditions affecting the head and neck. This innovative system features a self-shielded design that eliminates the necessity for traditional radiation vaults, allowing for greater accessibility and point-of-care delivery in settings such as physician offices, ambulatory surgery centers, and satellite facilities. By enabling neurosurgeons and radiation oncologists to utilize precision radiation more effectively, Zap Surgical Systems aims to enhance treatment options for patients requiring advanced surgical interventions.
Oncora Medical
Corporate Round in 2019
Oncora Medical, Inc. is a digital health company focused on enhancing radiation oncology through an innovative analytics platform. Founded in 2014 and based in Philadelphia, Pennsylvania, the company provides tools that facilitate the integration of clinical data from electronic medical records, treatment planning software, and oncology information systems. This allows radiation oncologists to make personalized treatment recommendations based on historical data and predictive analytics. The platform also employs machine learning algorithms to analyze patient outcomes, enabling oncologists to improve cancer care and optimize treatment strategies. By leveraging real-world data, Oncora Medical aims to support better healthcare decisions and ultimately enhance patient outcomes in radiation oncology.
Endocare
Acquisition in 2019
Endocare, Inc. is a company based in Austin, Texas, that specializes in the development, manufacturing, and distribution of medical devices and consumables for cryoablation. The company focuses on creating systems and disposable products designed for the cryoablation of prostate and kidney tissue, as well as for the freezing of nerves in pain management. By providing these innovative solutions, Endocare enables patients to effectively treat diseased tissue, enhancing their overall healthcare options.
Cancer Treatment Services International
Acquisition in 2019
Cancer Treatment Services International (CTSI) is a provider of comprehensive clinical and administrative solutions for cancer treatment and other complex diseases. Established in 2006 and headquartered in Pittsburgh, Pennsylvania, the company operates a network of cancer treatment facilities, including locations in Boca Raton, Florida; Chula Vista, California; and Hyderabad, India. CTSI specializes in services such as radiation oncology, medical oncology, surgical oncology, and full-service diagnostics, along with various support care services. The organization employs a centralized management approach that standardizes clinical pathways and operational processes, enhancing decision-making and ensuring a patient-centric environment. Initially focused on outpatient radiation therapy and medical oncology, CTSI aims to expand its offerings across multiple medical specialties, particularly in emerging markets.
Cyberheart
Acquisition in 2019
CyberHeart, Inc. is a clinical development-stage company based in Mountain View, California, focused on creating a non-invasive robotic ablation treatment for cardiac arrhythmias, including conditions like atrial fibrillation and ventricular tachycardia. The company's flagship product, the CyberHeart System, utilizes advanced technology to dynamically detect, track, and compensate for the movement of both the heart and the patient, ensuring precise radiation delivery. This system is designed for use by healthcare professionals such as radiation oncologists, medical physicists, electrophysiologists, and cardiac surgeons. Founded in 2003 and operating as a subsidiary of Varian Medical Systems as of April 2019, CyberHeart has been conducting pre-clinical studies to validate the feasibility of its innovative technology. The company has also secured venture capital financing to support its development efforts.
HistoSonics
Series C in 2019
HistoSonics, Inc. is a medical technology company based in Plymouth, Minnesota, specializing in non-invasive tumor ablation systems. The company has developed the Edison Platform, which employs advanced imaging and proprietary sensing technology to deliver precise sonic beam therapy. This innovative platform utilizes histotripsy and focused sound energy to liquefy and destroy targeted tissues at the sub-cellular level, enabling personalized treatments. HistoSonics' technology allows physicians to monitor the treatment in real time, offering a safe alternative to traditional interventional and surgical methods, minimizing undesirable side effects often associated with these approaches. Incorporated in 2009, HistoSonics aims to enhance treatment outcomes through its pioneering non-invasive solutions.
ABK Biomedical
Series B in 2019
ABK Biomedical Inc., founded in 2012 and based in Halifax, Canada, develops innovative embolotherapeutic products aimed at treating uterine fibroids, hypervascular tumors, and arteriovenous malformations. The company focuses on enhancing interventional radiology procedures, particularly embolization, by combining clinical market insights with advanced biomaterials. ABK Biomedical's flagship product is a novel radiopaque microsphere designed to improve the targeting of tumor blood vessels and tissue. This technology not only aids in the standardization and optimization of minimally invasive therapies but also facilitates personalized treatment options for patients with complex conditions. Through its commitment to advancing embolotherapy, ABK Biomedical seeks to transform patient care in the field of interventional radiology.
Fusion Pharmaceuticals
Series B in 2019
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.
Noona Healthcare
Acquisition in 2018
Noona Healthcare Oy, established in 2014 and headquartered in Helsinki, Finland, specializes in developing a Web-based mobile service called Noona. This platform enables breast cancer patients to directly report treatment-related symptoms to their clinics via mobile phones, tablets, and computers, fostering real-time, holistic patient monitoring. Additionally, Noona's platform facilitates scientific research by generating digital data that combines patient diagnosis, treatment, and genetic information, aiding in the development of new cancer therapies. As of 2018, Noona Healthcare operates as a subsidiary of Varian Medical Systems, Inc.
HumediQ Global
Acquisition in 2018
HumediQ Global, established in 2010 and headquartered in Grünwald, Germany, specializes in the development, manufacturing, and sales of medical-technical systems. With a team of 10, the company focuses on quality assurance systems in radiotherapy, creating innovative hardware and software solutions. Their flagship product is an automated patient identification, positioning, and motion management system for radiation therapy, featuring a palm reader for patient identification, automatic synchronization with oncology information systems, and surface-guided radiation therapy (SGRT) cameras for real-time patient positioning and motion monitoring. This enables healthcare professionals to enhance treatment quality and minimize errors. HumediQ works closely with hospitals and research institutions to integrate scientific research results into clinical practice. As of 2018, the company operates as a subsidiary of Varian Medical Systems, Inc.
Gamma Basics
Acquisition in 2018
Gamma Basics specializes in developing software applications tailored for the radiation oncology, nuclear medicine, and diagnostic imaging sectors. The company is known for grayCAD, a unique medical radiation safety computer-aided design software that allows users to design and analyze radiation shielding by utilizing architectural drawings and adhering to local shielding regulations. This software aids hospitals in evaluating their compliance with radiation safety standards, particularly when they upgrade their capital equipment. By focusing on enhancing safety protocols in medical environments, Gamma Basics plays a crucial role in ensuring that healthcare facilities meet regulatory requirements in radiation protection.
Cooperative CL Enterprises
Acquisition in 2018
Cooperative CL Enterprises, a distributor of radiotherapy equipment in Taiwan. COOP currently employs 45 people, and has represented Varian in Taiwan for more than 40 years.
Evinance Innovation
Acquisition in 2018
Evinance Innovation, based in Montreal, Canada, specializes in clinical decision support software. Its platform facilitates collaborative, evidence-based decisions between doctors and patients, aligning with leading guidelines like NCCN. Seamlessly integrating with various EHR systems and medical specialties, the platform enhances communication, promotes shared decision-making, and tracks adherence to recommendations. As of 2018, Evinance operates as a subsidiary of Varian Medical Systems.
Mobius Medical Systems
Acquisition in 2018
Mobius Medical Systems, based in Houston, Texas, specializes in developing radiation oncology quality assurance (QA) software aimed at improving treatment outcomes in cancer care. Founded in 2010, the company has established itself as a leader in the field, with its software utilized at over 1,000 sites globally to ensure the delivery of high-quality patient care. Key offerings include Mobius3D, a 3D dose verification system that supports verification checks throughout the clinical process for intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT). Additionally, DoseLab provides straightforward and effective QA for medical linear accelerators. As of 2018, Mobius Medical Systems operates as a subsidiary of Varian Medical Systems, further strengthening its impact in the radiation oncology sector.
Arterys
Series B in 2017
Arterys Inc. is a technology company that specializes in developing a cloud-based analytics platform designed to enhance medical imaging diagnostics. Founded in 2007 and headquartered in San Francisco, California, with additional offices in Calgary and Paris, Arterys offers a range of artificial intelligence solutions, including Cardio AI for cardiac image analysis, Lung AI for lung imaging, and Liver AI for liver assessments. Their platform provides radiologists with tools to visualize and quantify blood flow in the human body, facilitating improved patient care through advanced imaging techniques. The Arterys PHI Service allows physicians to access patient data remotely, enhancing the efficiency of medical practice. As a pioneer in internet-based medical imaging, Arterys combines web accessibility with FDA-cleared AI technology to deliver innovative clinical solutions aimed at transforming healthcare.
Fusion Pharmaceuticals
Series A in 2017
Fusion Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company headquartered in Hamilton, Canada, specializing in the development of radiopharmaceuticals as precision medicines for challenging cancers. The company employs its proprietary Targeted Alpha Therapies platform and Fast-Clear linker technology to connect alpha particle-emitting isotopes to antibodies, enabling the selective delivery of therapeutic agents to tumors. Fusion's lead product candidate, FPI-1434, is currently undergoing Phase 1 clinical trials as a monotherapy for solid tumors expressing insulin-like growth factor 1 receptor. Additionally, the company is exploring the use of FPI-1434 in combination with approved checkpoint inhibitors and DNA damage response inhibitors in preclinical studies to enhance anti-tumor activity. Fusion is also advancing another product candidate, FPI-1966, into clinical development for head and neck and bladder cancers that express fibroblast growth factor receptor. Founded in 2014 as a spinout of the Centre for Probe Development and Commercialization, Fusion aims to transform how cancers are treated through innovative radiochemistry techniques.
PerkinElmer's Medical Imaging Business
Acquisition in 2016
Varex's components are used in medical imaging as well as in industrial and security imaging applications. Global OEM manufacturers.
Candela's radiotherapy business
Acquisition in 2016
Candela's radiotherapy business is a distributor of radiotherapy equipment in Poland.
TrueBeam Systems
Acquisition in 2016
TrueBeam systems will enable us to make advanced cancer care accessible to even more patients.
Claymount Technologies
Acquisition in 2015
Claymount is a designer and manufacturer wants to add value to your X-ray system through Technology Excellence and Cost Leadership.
MeVis Medical Solutions
Acquisition in 2015
MeVis Medical Solutions AG is a provider of software solutions focused on the analysis and evaluation of medical imaging data, catering to equipment manufacturers and medical IT platform providers in the United States and Europe. The company operates in two primary segments: Digital Mammography and Other Diagnostics. The Digital Mammography segment develops software to support breast diagnostic imaging and interventions, including applications for various imaging modalities like ultrasound and magnetic resonance imaging. The Other Diagnostics segment offers digital radiology products aimed at diagnosing conditions such as lung, prostate, and intestinal disorders, alongside general image analysis services. Additionally, MeVis provides interactive online training to enhance diagnostic capabilities for clinical users. Founded in 1992 and based in Bremen, Germany, MeVis Medical Solutions operates as a subsidiary of Varex Imaging Deutschland AG.
Transpire
Acquisition in 2014
Transpire, Inc. develops simulation software products that predict the macroscopic behavior of radiation for various industries.
Velocity Medical Solutions
Acquisition in 2014
Velocity Medical Solutions develops advanced imaging software aimed at enhancing cancer treatment, focusing primarily on radiation therapy. The company specializes in oncology Picture Archiving and Communication Systems (PACS) that serve various markets, including research, clinical practice, and drug discovery. Its flagship product, VelocityAI, is an imaging informatics tool that facilitates the rapid development of radiation therapy plans and introduces innovative methods for evaluating treatment effectiveness. Additionally, VelocityGRID is a vendor-neutral platform that consolidates image, structure, plan, and dose data into a comprehensive patient dataset, regardless of data source. VelocityConnect fosters collaboration between oncologists and referring physicians, further streamlining the treatment process. Through these offerings, Velocity Medical Solutions aims to improve the planning and efficacy of cancer therapies.
Applied Computational Technologies
Acquisition in 2013
Applied Computational Technologies is a software development company that specializes in applications for the life sciences, particularly in radiation treatment planning for cancer therapy. With a significant number of cancer diagnoses in the United States, a large portion of patients undergo radiation treatment, highlighting the importance of effective planning tools. The company's flagship product, ProACTive, serves as a dose calculation engine that facilitates adaptive radiotherapy, enhancing the precision and effectiveness of cancer treatment. Through its innovative software solutions, Applied Computational Technologies aims to improve patient outcomes in the challenging field of oncology.
Infimed
Acquisition in 2012
Infimed, Inc. provides software and hardware for medical imaging. The company specializes in digital medical imaging systems for fluoroscopy, angiography, cardiology, general radiography, and digital radiography. It offers i5 DR, a digital radiography imaging system for dealers and OEM; and i5 RF/DSA, a digital fluoroscopy imaging system to acquire, review and alter, store, export, and print images. The company also provides iCynergy to acquire RF camera and static wireless DR panel images; PlatinumOne that improves the productivity of fluoroscopy, angiography, urology, and cardiology procedures; and i5 Nexus-DRF that includes InfiVision, an automatic image enhancement software. It serves customers in Asia, Europe, North America, the Russian Federation, China, and South America. The company was founded in 1983 and is based in Liverpool, New York. As of April 3, 2012, Infimed, Inc. operates as a subsidiary of Varian Medical Systems Inc
Calypso Medical
Acquisition in 2011
Calypso Medical Technologies, based in Seattle, is a privately held medical device company specializing in tumor localization technology. The company's proprietary system employs miniaturized implanted devices known as Beacon electromagnetic transponders to continuously and accurately track the location of tumors, enhancing the precision and management of radiation therapy delivery. This technology is particularly aimed at body-wide cancers that are commonly treated with radiation. Calypso's products have received FDA 510(k) clearance for use in the prostate and post-operative prostatic bed, ensuring compliance with regulatory standards. The company has established strategic partnerships with leading organizations in the medical field, including Varian Medical Systems, Siemens Medical Systems, Elekta Corporation, and Philips Medical, to further its mission of improving cancer treatment outcomes.
SpaceOAR
Series C in 2011
SpaceOAR is a privately held medical device company developing in-situ formed, space-filling hydrogels specifically for radiation oncology and cancer surgery indications. Its hydrogel is clinically proven to minimize side effects and protect the quality of life for prostate cancer patients undergoing radiation therapy that enables healthcare providers to minimize urinary, sexual, and bowel side effects of the patients. It was founded in 2007 and is headquartered in Bedford, Massachusetts.
IKOEmed
Acquisition in 2009
IKOEngelo, a medical knowledge-based system that enables the practice to operate IMRT at various levels of quality and efficiency.
Pan-Pacific Enterprises
Acquisition in 2007
Pan-Pacific Enterprises, Inc. distributes medical diagnostic equipment in China, the United states, and internationally.
Bio-Imaging Research
Acquisition in 2007
Bio-Imaging Research. designs and manufactures medical and industrial imaging systems for medical‚ industrial‚ and security applications.
Accel Instruments GmbH
Acquisition in 2007
ACCEL Instruments GmbH, a privately held supplier of scientific research instruments and proton therapy systems for cancer treatment.
Sigma Micro Informatique Conseil
Acquisition in 2005
Sigma Micro Informatique Conseil, a privately-held company that is the leading supplier of information management software for radiation oncology and medical oncology in cancer clinics and hospitals in France and other European nations. Varian paid approximately $13 million in cash to acquire the company, which is based in Toulouse, France.
OpTx Corp
Acquisition in 2004
OpTx Corporation develops solutions for oncology practices in the areas of patient management.
Zmed
Acquisition in 2003
Zmed, Inc. supplies stereotactic radiosurgery and precision radiotherapy products.Developer of radiation oncology software intended to improve clinical performance in medical imaging intensive applications. The company supplies radiation oncology software and accessories for ultrasound-based, image-guided radiotherapy (IGRT), stereotactic radiation treatments and image management.
MRW GmbH
Acquisition in 2002
MRW GmbH, a prominent reloader and distributor of medical X-ray tubes in Germany.
MDS Nordion's - (HDR) Brachytherapy Business
Acquisition in 2002
HDR brachytherapy a minimally invasive procedure for eradicating cancerous tumors with radiation.
Argus Software
Acquisition in 2002
Argus Software, Inc designs and develops quality control information management software.
IMPAC Medical Systems
Acquisition in 2000
IMPAC Medical Systems, Inc. specializes in providing information technology solutions for cancer care across North America, Europe, and Asia. The company offers a range of products including device connectivity systems, medical imaging solutions, practice management systems, anatomic pathology systems, and data aggregation and reporting tools. These offerings are designed to deliver integrated clinical and administrative solutions that address the complexities of cancer care, from detection and diagnosis to treatment and follow-up. Additionally, IMPAC provides services such as implementation, training, support, upgrades, transition management, network services, and remote hosting. Through its comprehensive oncology management system, IMPAC aims to enhance clinical and business operations, ultimately improving the efficiency and quality of patient care in healthcare facilities.
Multimedia Medical Systems - Cancer Treatment Planning Systems Division
Acquisition in 1999
Multimedia Medical Systems, Inc. of Charlottesville, Va., to expand its product line for addressing the treatment of prostate cancer.
dpiX
Acquisition in 1999
dpiX is a a-Si technology firm that focuses on research, engineering, development, and manufacturing.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.